# Table of Contents

## Summary

## Basics
- Definition
- Epidemiology
- Etiology
- Pathophysiology
- Classification

## Prevention
- Secondary prevention

## Diagnosis
- Case history
- Step-by-step diagnostic approach
- Risk factors
- History & examination factors
- Diagnostic tests
- Differential diagnosis
- Diagnostic criteria

## Treatment
- Step-by-step treatment approach
- Treatment details overview
- Treatment options
- Emerging

## Follow up
- Recommendations
- Complications
- Prognosis

## Guidelines
- Diagnostic guidelines
- Treatment guidelines

## Online resources

## References

## Images

## Disclaimer
Systemic autoimmune disease triggered by dietary gluten peptides found in wheat, rye, barley, and related grains.

Common, affecting up to 1% of the general population, and may present at any age.

Presentation is varied and ranges from diarrhea and failure to thrive, to iron-deficiency anemia or osteoporosis.

Diagnosis is suggested by positive immunoglobulin A tissue transglutaminase serology, but must be confirmed by duodenal biopsy and histology.

The only current therapy is a strict, lifelong gluten-free diet.

Complications of untreated celiac disease include gastrointestinal symptoms, malabsorption, increased risk of malignancy, and higher overall mortality than in the general population.
Definition

Celiac disease is a systemic autoimmune disease triggered by dietary gluten peptides found in wheat, rye, barley, and related grains. Immune activation in the small intestine leads to villous atrophy, hypertrophy of the intestinal crypts, and increased numbers of lymphocytes in the epithelium and lamina propria. Locally these changes lead to gastrointestinal symptoms and malabsorption. Systemic manifestations are diverse, potentially affecting almost every organ system.

Epidemiology

Celiac disease is a common disorder in the US and in Europe. A relatively uniform prevalence has been found in many countries, ranging between 1 in 67 and 1 in 250 with an approximate average of 1% in well-designed studies from diverse areas including North and South America, eastern and western Europe, Turkey, the Middle East, and North Africa.[1] [2] [3] [4] [5] [6] [7] [8] [9] It is far less common in people from southeast Asia and sub-Saharan Africa.

In population studies, men and women are roughly equally affected. In clinical practice, however, women tend to make up almost two-thirds of patients. The first peak period of presentation is in childhood around age 6 to 7 years, but celiac disease can arise as soon as gluten is introduced. A second, larger peak occurs in the fourth and fifth decades. Although the most common age at diagnosis in the US is about 40 years, celiac disease may be diagnosed at any age.[10] [11]

Silent celiac disease is serologic and histologic evidence of celiac disease, but without any evident symptoms, signs, or deficiency states. The proportion of celiac disease that is truly silent is not well known, but it is thought to account for at least 20% of cases.

Refractory celiac disease is a specific diagnosis within the category of nonresponsive celiac disease, defined as the persistence of clinical symptoms and histologic abnormalities after at least 6 months on a strict gluten-free diet and in the absence of other evident causes or of overt lymphoma. The incidence of refractory celiac disease in patients with celiac disease is not well known but is felt to be approximately 1%.

Etiology

Celiac disease is a systemic autoimmune disorder triggered by gluten peptides from grains including wheat, rye, and barley. Almost all people with celiac disease carry one of 2 major histocompatibility complex class-II molecules (HLA-DQ2 or -DQ8) that are required to present gluten peptides in a manner that activates an antigen-specific T cell response. The requirement for DQ2 or DQ8 is a major factor in the genetic predisposition to celiac disease. However, most DQ2- or DQ8-positive people never develop celiac disease despite daily exposure to dietary gluten. The additional environmental or genetic factors that are required for loss of immune tolerance to dietary gluten are unknown. Factors that have been hypothesized to play a role include: the timing of initial gluten exposure; gastrointestinal infection leading to gluten antigen mimicry; or direct damage to the intestinal-epithelial barrier leading to abnormal exposure of the mucosa to gluten peptides.
**Pathophysiology**

Loss of immune tolerance to gliadin peptide antigens derived from wheat, rye, barley, and related grains is the central abnormality of celiac disease. These peptides are resistant to human proteases, allowing them to persist intact in the small intestinal lumen.[12] It is unknown how these peptides gain access to the lamina propria, but leading hypotheses include faulty tight junctions, endothelial cell transcytosis, sampling of the intestinal lumen by dendritic cells, and passage during resorption of apoptotic villous enterocytes.

In the intestinal submucosa these peptides trigger both innate and adaptive immune activation. The mechanism of innate immune activation is not fully known. Gluten peptides are clearly able to stimulate interleukin-15 production by dendritic cells and macrophages, which then stimulate intraepithelial lymphocytes, leading to epithelial damage.[13] [14] In the submucosa, gluten peptides are deamidated by tissue transglutaminase (tTG), an enzyme normally involved in collagen cross-linking and tissue remodeling. Deamidation of the gliadin peptide allows for, first, high-affinity binding to the celiac-associated HLA peptides (DQ2 or DQ8) found on antigen-presenting cells, and second, activation of helper T (Th) cells.[15] For this reason people must carry either HLA-DQ2 (95% of patients with celiac disease) or -DQ8 (5% of patients with celiac disease) to develop celiac disease. Stimulation of Th cells has 2 consequences. Cell death and tissue remodeling with villous atrophy and crypt hyperplasia are induced by Th1-derived cytotoxic T lymphocytes. Th2 triggers plasma cell maturation and subsequent antigliadin and anti-tTG antibody production.[16]

**Classification**

**Subgroups of celiac disease**

There is no formal classification of celiac disease; however, it can be divided into common subgroups.

1. Classic celiac disease: typical symptoms including diarrhea, weight loss, abdominal pain and discomfort, and fatigue. Classic symptoms are found in <50% of patients.
2. Atypical celiac disease: lacks the typical gastrointestinal symptoms of malabsorption; presents with deficiency states (e.g., iron deficiency) or extraintestinal manifestations (e.g., fatigue, elevated liver enzymes, or infertility). However, atypical disease likely accounts for the largest proportion of patients with a diagnosis of celiac disease.
3. Silent celiac disease: serologic and histologic evidence of celiac disease, but without any evident symptoms, signs, or deficiency states. The proportion of celiac disease that is truly silent is not well known, but it is thought to account for at least 20% of cases.
4. Nonresponsive celiac disease: clinical symptoms or laboratory abnormalities typical of celiac disease fail to improve within 6 months of gluten withdrawal, or typical symptoms or laboratory abnormalities recur while the patient is on a gluten-free diet.
5. Refractory celiac disease: specific diagnosis within the category of nonresponsive celiac disease, defined as the persistence of clinical symptoms and histologic abnormalities after at least 6 months on a strict gluten-free diet and in the absence of other evident causes or of overt lymphoma. The incidence of refractory celiac disease in patients with celiac disease is not well known but is felt to be approximately 1%.
Secondary prevention

The current accepted approach is aggressive case finding with vigilance for the many potential manifestations of celiac disease and a low threshold for serologic testing. Perhaps the group of most concern is young children with a first-degree relative with celiac disease, as the approximate 7% risk of celiac disease is considerable and delayed diagnosis has the potential to lead to a permanent loss in growth potential. For this reason serologic testing may be considered before the onset of symptoms in at-risk children. Well-designed, randomized clinical trials do not suggest that either breastfeeding or timing of gluten introduction into the diet alter the risk of celiac disease in children with a family history of celiac disease.[78] [79] [80]
Case history

Case history #1

A 46-year-old woman presents with fatigue and is found to have iron deficiency with anemia. She has experienced intermittent episodes of mild diarrhea for many years, previously diagnosed as irritable bowel syndrome and lactose intolerance. She has no current significant gastrointestinal symptoms. Examination reveals 2 oral aphthous ulcers and pallor. Abdominal examination is normal and results of fecal testing for occult blood are negative.

Other presentations

Atypical presentations include an asymptomatic patient, elevated liver enzymes, vitamin D deficiency, osteopenia or osteoporosis, constipation, aphthous stomatitis, nausea or vomiting, heartburn or gastroesophageal reflux disease, hyposplenia or asplenia, myalgias, arthralgias, peripheral neuropathy, alopecia, headaches, infertility, and adverse pregnancy outcomes.

Step-by-step diagnostic approach

Celiac disease can present in many varied ways and requires a high degree of clinical suspicion.

Presenting features

Patients with unexplained gastrointestinal symptoms (including those diagnosed with irritable bowel syndrome and/or dyspepsia), chronic diarrhea, unexplained iron deficiency anemia, or a skin rash consistent with dermatitis herpetiformis should be tested for celiac disease.[27] [28] Other situations that may prompt testing include failure to thrive, short stature, vitamin deficiency (B12, D, or folate), recurrent severe aphthous stomatitis, recurrent spontaneous abortion, and infertility.[29]

Investigations

Before testing, it is crucial to ensure that the patient is ingesting gluten, because all diagnostic tests will normalize on a gluten-free diet.

1. Serology

- Immunoglobulin A-tissue transglutaminase (IgA-tTG) titer should be evaluated.[30] [31] Although not supported by evidence, quantitative IgA is often routinely requested to assess for IgA deficiency.
- Endomysial antibody (EMA) is a more expensive alternative to IgA-tTG, with greater specificity but lower sensitivity, which may be used if IgA-tTG is unavailable.[32] Unlike tTG, which is an ELISA, EMA is based on immunofluorescence and thus is operator dependent.
- In cases of IgA deficiency, request IgG-deamidated gliadin peptide (DGP) serology, although the diagnostic accuracy of this test is somewhat less than that of IgA-tTG.[31] [33] Patients with an elevated IgA-tTG level should be advised to remain on a gluten-containing diet and referred for duodenal biopsy. It is also reasonable to proceed to duodenal biopsy in patients with IgA deficiency. IgG-tTG was previously one of the common serologic tests for celiac disease in individuals with...
known or suspected IgA deficiency. However, this test has been largely replaced by the newer and more accurate IgG DGP or IgA/IgG DGP.

- A normal IgA-tTG and total IgA test result are adequate to exclude a diagnosis in patients with a low clinical index of suspicion for celiac disease.

2. Histology

- Patients with an elevated IgA-tTG level should be advised to remain on a gluten-containing diet and referred for duodenal biopsy.

- Small intestinal biopsies should be obtained regardless of the IgA-tTG result in patients with a high clinical index of suspicion. However, pediatric patients with symptoms consistent with celiac disease and a high IgA-tTG titer (above normal range for laboratory) may go on to have confirmatory EMA and HLA-DQ2/-DQ8 testing. If both of these are positive, celiac disease may be considered confirmed without a small intestinal biopsy. However, the accuracy and cost-effectiveness of this strategy has not been rigorously evaluated in adults or outside of European populations.[34]

- Duodenal biopsy changes in celiac disease are typically graded by the Marsh classification, from 0 to 4.[35] To diagnose celiac disease, intraepithelial lymphocytes should be increased and the villous-to-crypt ratio decreased. The presence of only one of these changes raises the possibility of a different diagnosis.

[Fig-1]

- The presence of typical celiac changes on duodenal histology with clinical improvement on a gluten-free diet confirms the diagnosis. A repeat duodenal biopsy after gluten withdrawal is no longer routinely necessary for verification.

[Fig-2]

[Fig-3]

[Fig-4]

3. HLA testing

- May be used to rule out celiac disease in patients already on a gluten-free diet or in patients with an idiopathic celiac-like enteropathy, but is not helpful for diagnosis.

4. Endoscopy

- Atrophy and scalloping of mucosal folds; nodularity and mosaic pattern of mucosa may be seen, but the endoscopic appearance of the small bowel is generally not helpful in diagnosis.

[Fig-5]

[Fig-6]

**Gluten challenge**

People with celiac disease on a gluten-free diet prior to evaluation cannot be differentiated from healthy controls. In these cases, gluten challenge is necessary. In a gluten challenge, the person is placed back on a gluten-containing diet, with serologic tests and small bowel histology assessed after 2 to 8 weeks on the gluten-containing diet.[36]
Home-performed quick tests

Rapid finger-stick tTG tests are available that can give a positive or negative results either at home or at the bedside. Results are available within 30 minutes. Accuracy appears similar to that of standard tTG testing, but the lack of a titer that can be followed over time is a disadvantage. The clinical role for this is still being evaluated, but clearly in areas where a lab for running standard tests is not available, point-of-care testing should be considered.

Saliva celiac genetic tests can show the presence of the HLA-DQ2 or HLA-DQ8 genes. It is important to counsel that having these genes is not equivalent to having celiac disease, and having these genes alone does not have any known prognostic value. If the test is negative, a person's risk for celiac disease is extremely low.

Risk factors

Strong

FHx of celiac disease

• Multiple studies have shown an increased risk in family members, likely secondary to genetic factors.[17]

IgA deficiency

• Multiple studies have shown an association between IgA deficiency and celiac disease. Although the pathogenesis is unclear, it has been proposed that a lack of secretory IgA and Peyer patch malfunction allow for increased free gluten peptides in the submucosa.[18]

type 1 diabetes

• Multiple studies have shown an association between type 1 diabetes mellitus and celiac disease. This is probably due to genetic factors favoring autoimmunity. Leaky gut, with tight junction defects leading to increased passage of luminal peptides into the submucosa, resulting in immune activation, is also hypothesized.[19] [20]

autoimmune thyroid disease

• Multiple studies have shown an association between thyroid disease and celiac disease. Pathogenesis is similar to that of type 1 diabetes mellitus.[21]

Weak

Down syndrome

• Many studies show an association between Down syndrome and celiac disease, although one study refutes this. The mechanism is unclear because celiac disease does not appear to be linked to genes found on chromosome 21.[22] [23]

Sjogren syndrome

• Some studies have shown an increased prevalence of celiac disease in patients with Sjogren syndrome.[24]
inflammatory bowel disease

• A few studies have shown an increased prevalence of celiac disease in patients with Crohn disease and, to a lesser extent, ulcerative colitis.[25]

primary biliary cirrhosis

• Studies have shown an increased prevalence of celiac auto-antibodies in patients with primary biliary cirrhosis and other liver diseases, but false positives appear higher in these populations.[26]

History & examination factors

Key diagnostic factors

IgA deficiency (common)

• Multiple studies have shown an association between IgA deficiency and celiac disease. Although the pathogenesis is unclear, it has been proposed that a lack of secretory IgA and Peyer patch malfunction allow for increased free gluten peptides in the submucosa.[18]

diarrhea (common)

• Patients with longstanding or refractory abdominal symptoms should be screened for celiac disease.[30] Patients may present with chronic or intermittent diarrhea.

bloating (common)

• Patients with longstanding or refractory abdominal symptoms should be screened for celiac disease.[30]

abdominal pain/discomfort (common)

• Patients with longstanding or refractory abdominal symptoms should be screened for celiac disease.[30] Patients may present with recurrent abdominal pain, cramping, or distension.[38]

anemia (common)

• Iron deficiency anemia is the most common clinical presentation in adults. Folate (and rarely vitamin B12) deficiency may lead to a macrocytic anemia.[39]

dermatitis herpetiformis (uncommon)

• Characterized by intensely pruritic papulovesicular lesions that occur symmetrically over the extensor surfaces of the arms and legs, as well as on the buttocks, trunk, neck, and scalp.[39] Biopsy-proven dermatitis herpetiformis almost universally occurs in association with celiac disease.

Other diagnostic factors

FHx (common)

• FHx of celiac disease or other autoimmune disorders.

osteopenia/osteoporosis (common)

• History of bone pain or previous fracture, due to vitamin D deficiency and hypocalcemia.

fatigue (common)
Celiac disease

• Associated with iron deficiency anemia.[39]

**weight loss (common)**
• Likely multifactorial, primarily due to malabsorption but also to changes in motility, metabolism, and appetite.[39]

**failure to thrive (common)**
• In children, faltering growth and delayed puberty are indications for testing for celiac disease.[40]

**type 1 diabetes (uncommon)**
• Clinicians caring for patients with type 1 diabetes mellitus should be aware of the association with celiac disease and consider testing if symptoms occur.[37]

**autoimmune thyroid disease (uncommon)**
• Clinicians caring for patients with autoimmune thyroid disease should be aware of the association with celiac disease and consider testing if symptoms occur.[37]

**aphthous stomatitis (uncommon)**
• Caused by various nutritional deficiencies, although the particular deficiency is not always evident.[41] May be recurrent.

**dental enamel hypoplasia (uncommon)**
• The exact etiology is unclear but is felt to be due to nutritionally derived abnormalities in mineralization.

**alopecia (uncommon)**
• Alopecia areata is an autoimmune disease associated with celiac disease that may be reversed with a gluten-free diet.

**easy bruising (uncommon)**
• Vitamin K deficiency may lead to a coagulopathy.

**peripheral neuropathy (uncommon)**
• The etiology of neurologic dysfunction may be the result of either vitamin deficiencies (B12, E, or D; folate or pyridoxine) or autoimmune activity against neural antigens.[41]

**ataxia (uncommon)**
• Cerebellar ataxia is one of the more common neurologic symptoms.[41]
## Diagnostic tests

### 1st test to order

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC and blood smear</td>
<td>low Hb and microcytic red cells</td>
</tr>
<tr>
<td>• Iron deficiency anemia is the most common clinical presentation in adults.</td>
<td></td>
</tr>
<tr>
<td>• Folate (and rarely vitamin B12) deficiency may lead to a macrocytic anemia.[39]</td>
<td></td>
</tr>
<tr>
<td>IgA-tTG</td>
<td>titer above normal range for laboratory</td>
</tr>
<tr>
<td>• Order an immunoglobulin A-tissue transglutaminase (IgA-tTG) test in any case of suspected celiac disease.[30]</td>
<td></td>
</tr>
<tr>
<td>• Higher titers have increased positive predictive value.</td>
<td></td>
</tr>
<tr>
<td>EMA</td>
<td>elevated titer</td>
</tr>
<tr>
<td>• Endomysial antibody (EMA) is a more expensive alternative to IgA-tTG with greater specificity but lower sensitivity.</td>
<td></td>
</tr>
<tr>
<td>• Perform initially if IgA-tTG is unavailable.[32]</td>
<td></td>
</tr>
<tr>
<td>skin bx</td>
<td>granular deposits of IgA at the dermal papillae of lesional and perilesional skin by direct immunofluorescence</td>
</tr>
<tr>
<td>• Order this test initially in any cases of skin lesions suggestive of dermatitis herpetiformis.</td>
<td></td>
</tr>
<tr>
<td>• Both sensitivity and specificity are high.</td>
<td></td>
</tr>
<tr>
<td>IgG DGP or IgA/IgG DGP (deamidated gliadin peptide)</td>
<td>elevated titer</td>
</tr>
<tr>
<td>• Test of choice for individuals with IgA deficiency.</td>
<td></td>
</tr>
<tr>
<td>IgG-tTG</td>
<td>elevated titer</td>
</tr>
<tr>
<td>• IgG-tTG was previously one of the common serologic tests for celiac disease in individuals with known or suspected IgA deficiency. However, this test has been largely replaced by the newer and more accurate IgG DGP or IgA/IgG DGP (deamidated gliadin peptide).</td>
<td></td>
</tr>
</tbody>
</table>

### Other tests to consider

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA typing</td>
<td>positive HLA-DQ2 or -DQ8</td>
</tr>
<tr>
<td>• This genetic test is useful to rule out celiac disease in patients already on a gluten-free diet or in patients with an idiopathic celiac-like enteropathy.</td>
<td></td>
</tr>
<tr>
<td>small bowel - macroscopic</td>
<td>atrophy and scalloping of mucosal folds; nodularity and mosaic pattern of mucosa</td>
</tr>
<tr>
<td>• The endoscopic appearance is generally not helpful in diagnosis. [Fig-5]</td>
<td></td>
</tr>
<tr>
<td>[Fig-6]</td>
<td></td>
</tr>
</tbody>
</table>
### Celiac disease

#### Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>small bowel - histology</strong></td>
<td>presence of intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia</td>
</tr>
<tr>
<td>• Small-bowel histology is the most specific and sensitive test.</td>
<td></td>
</tr>
<tr>
<td>• If possible, grade the results according to the Marsh criteria.</td>
<td></td>
</tr>
<tr>
<td>• Perform small-bowel histology in cases of positive serology or IgA deficiency or in cases of high clinical suspicion despite negative serology.</td>
<td></td>
</tr>
<tr>
<td>• Pediatric patients with symptoms consistent with celiac disease and a high IgA-tTG titer (above normal range for laboratory) may go on to have confirmatory EMA and HLA-DQ2/-DQ8 testing. If both of these are positive, celiac disease may be considered confirmed without a small intestinal biopsy.[34]</td>
<td></td>
</tr>
<tr>
<td>• Both sensitivity and specificity are high.</td>
<td></td>
</tr>
<tr>
<td>[Fig-1]</td>
<td></td>
</tr>
<tr>
<td>[Fig-2]</td>
<td></td>
</tr>
</tbody>
</table>

| gluten challenge             | increase in celiac serologic tests and presence of intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia on small intestinal biopsy |
| • People with celiac disease on a gluten-free diet prior to evaluation cannot be differentiated from healthy controls. In these cases, gluten challenge is necessary. In a gluten challenge, the person is placed back on a gluten-containing diet, with serologic tests and small bowel histology assessed after 2 to 8 weeks on the gluten-containing diet.[36] |                                             |

#### Emerging tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>point-of-care tTG testing</strong></td>
<td>positive or negative</td>
</tr>
<tr>
<td>• Rapid finger-stick tTG tests are now available that can give a positive or negative result either at home or at the bedside. Results are available within 30 minutes. Accuracy appears similar to standard tTG testing, but the lack of a titer that can be followed over time is a disadvantage. The clinical role for this is still being evaluated, but clearly in areas where a lab for running standard tests is not available, point-of-care testing should be considered.</td>
<td></td>
</tr>
</tbody>
</table>

| saliva celiac genetic test    | positive or negative for either HLA-DQ2 or HLA-DQ8 |
| • It is important to counsel that having HLA-DQ2 or HLA-DQ8 is not equivalent to having celiac disease, and having these genes alone does not have any known prognostic value. If this test is negative, a person’s risk for celiac disease is extremely low. |                                             |
## Differential diagnosis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptic duodenitis</td>
<td>• Patients present with chronic or recurrent abdominal pain or discomfort centered in the upper abdomen that is commonly related to eating. There may be a history of nonsteroidal anti-inflammatory drug (NSAID) use and use of antacid medications to relieve the discomfort.</td>
<td>• Peptic duodenitis is associated with acid injury and leads to a spectrum of histologic mucosal changes that may be difficult to distinguish from that seen in celiac disease. For this reason it is recommended that biopsies are not taken in the duodenal bulb, but rather in the second or third portion of the duodenum, which are relatively protected from peptic injury.</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>• Crohn disease can affect any part of the gastrointestinal tract, and symptoms may be extremely variable.</td>
<td>• The classic findings on histologic examination include granulomas, ulcerations, and acute and chronic inflammation often extending throughout all layers of bowel wall. • Tissue transglutaminase (tTG) serology is usually negative and there should be no response to gluten withdrawal.</td>
</tr>
<tr>
<td>Giardiasis</td>
<td>• Giardiasis is a diarrheal illness caused by infection with a waterborne parasite, <em>Giardia lamblia</em>. A history of exposure to contaminated water may suggest the diagnosis.</td>
<td>• Multiple stool specimens usually reveal the parasite. Alternative methods for detection are antigen detection tests by enzyme immunoassays and detection of parasites by immunofluorescence.</td>
</tr>
<tr>
<td>Small-intestinal bacterial overgrowth</td>
<td>• History may show conditions that alter intestinal anatomy, motility, and gastric acid secretion (such as use of proton pump inhibitors or anatomic disturbances in the bowel, including fistulae, diverticula, and blind loops created after surgery).</td>
<td>• The definitive investigation requires culture of jejunal fluid that grows in excess of $10^5$ bacteria/mL. Hydrogen breath testing may show malabsorption but is not very sensitive or specific for bacterial overgrowth. A trial of treatment with antibiotics for 1 week may give the diagnosis.</td>
</tr>
<tr>
<td>Condition</td>
<td>Differentiating signs / symptoms</td>
<td>Differentiating tests</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Postgastroenteritis</td>
<td>• In some children a clinical episode indistinguishable from acute gastroenteritis is followed by protracted diarrhea. This may be related to prolonged rotavirus infection[46] or transient lactose intolerance.</td>
<td>• Usually no investigations are required.</td>
</tr>
<tr>
<td>Eosinophilic enteritis</td>
<td>• Eosinophilic enteritis may affect any part of the alimentary canal and can present with anemia, diarrhea, abdominal pain, and weight loss. Often no cause is identified, although nematode infections are often isolated.[47]</td>
<td>• Diagnosis follows endoscopic or laparoscopic biopsy of the affected bowel with histology showing eosinophilic infiltrates.[47]</td>
</tr>
<tr>
<td>Tropical sprue</td>
<td>• Tropical sprue is a disease that causes progressive villous atrophy in the small intestine that is similar to celiac sprue. It is believed to be initiated or sustained by a still-undefined infection. The relapse rate is substantial in treated patients who remain in, or return to, endemic areas in the tropics.[48]</td>
<td>• Antibiotic therapy with tetracyclines for 6 months normalizes mucosal structure in the small intestine.[48]</td>
</tr>
<tr>
<td>CVID and other immunodeficiency states</td>
<td>• Common variable immune deficiency (CVID) and related disorders have a history of recurrent infections.</td>
<td>• Negative tTG serology and decreased immunoglobulin levels suggest immunodeficiency.</td>
</tr>
<tr>
<td>GVHD</td>
<td>• Graft-versus-host disease (GVHD) can occur with any organ transplantation but is most common after bone marrow transplantation. Patients have high-volume watery diarrhea about 3 weeks after transplantation if GVHD is present.[49]</td>
<td>• Endoscopic biopsy showing the presence of increased numbers of apoptotic epithelial cells in the intestinal crypts is diagnostic.[49]</td>
</tr>
<tr>
<td>Autoimmune enteropathy</td>
<td>• This condition is characterized by villous atrophy that is unresponsive to any dietary restrictions.[50]</td>
<td>• Negative for immunoglobulin A antigliadin and antiendomysial antibodies. Immunofluorescence staining may show enterocyte antibodies.[50]</td>
</tr>
</tbody>
</table>
## Celiac disease

### Diagnosis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-induced enteropathy</td>
<td>• May be clinically and pathologically indistinguishable from celiac disease.</td>
<td>• tTG serology is normal.</td>
</tr>
<tr>
<td></td>
<td>• Olmesartan, an angiotensin-II receptor antagonist, has been associated with enteropathy.[51]</td>
<td>• Symptoms remit once causative drug is stopped.</td>
</tr>
<tr>
<td></td>
<td>• There have also been case reports with other angiotensin-II receptor antagonists and mycophenolate.[52]</td>
<td></td>
</tr>
</tbody>
</table>

### Diagnostic criteria

#### Marsh criteria[35]

Histologic changes on small intestinal biopsy

- 0: normal villous architecture with no increase in intraepithelial lymphocytes
- I: normal villous architecture with increased intraepithelial lymphocytes
- II: increased intraepithelial lymphocytes and crypt hyperplasia with normal villi
- IIIa: increased intraepithelial lymphocytes and crypt hyperplasia with partial villous atrophy
- IIIb: increased intraepithelial lymphocytes and crypt hyperplasia with subtotal villous atrophy
- IIIc: increased intraepithelial lymphocytes and crypt hyperplasia with total villous atrophy.
Step-by-step treatment approach

The only accepted treatment of celiac disease is a strict lifelong gluten-free diet.

**Dietary advice**

The diet should not be started until definitive diagnosis has been made by small intestinal histology. After diagnosis the patient should be referred to a nutritionist with specific training in celiac disease and the gluten-free diet. Gluten-free diet adherence has been shown to be difficult, with dietary lapses in the majority of patients. For this reason the importance of the diet should be stressed, and social support evaluated and encouraged within the family and by membership in celiac disease advocacy groups.

**Supplementation**

After diagnosis, patients should be checked for common deficiencies including iron and vitamin D. All patients with celiac disease should be recommended to take calcium and vitamin D supplements. Iron should only be given to individuals with iron deficiency. Bone mineral density should be evaluated after approximately 1 year on a gluten-free diet to assess for osteopenia or osteoporosis.

**Failure to respond to treatment**

For individuals who do not respond to a gluten-free diet, the most common problem is continued gluten exposure. The initial step in the evaluation should be repeating immunoglobulin A-tissue transglutaminase (IgA-tTG) titer and referral to a nutritionist with expertise in celiac disease. If there is no evidence of continuing gluten intake, referral to a gastroenterologist with experience in the evaluation of nonresponsive celiac disease is recommended.

Refractory celiac disease is defined as the persistence of villous atrophy despite strict gluten withdrawal and no evidence of another abnormality including overt lymphoma. It is present in <1% of patients with celiac disease and is felt to be a spectrum determined by T-cell clonality and loss of normal intraepithelial cell markers. Common associations with refractory celiac disease include ulcerative jejunitis and enteropathy-associated T-cell lymphoma. The outlook for patients is generally poor. They should be cared for at a center experienced in celiac disease.

**Celiac crisis**

Celiac crisis is rare and presents with hypovolemia, severe watery diarrhea, acidosis, hypocalcemia, and hypoalbuminemia. Patients are often emaciated and have nutritional deficiencies caused by longstanding, untreated celiac disease. In addition to rehydration and correction of electrolyte abnormalities, these few patients may benefit from a short course of systemic glucocorticoid therapy until the gluten-free diet takes effect.

**Treatment details overview**

Consult your local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing. (see Disclaimer)
<table>
<thead>
<tr>
<th>Ongoing</th>
<th>(summary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>celiac disease</td>
<td>1st gluten-free diet plus calcium and vitamin D supplementation ± iron</td>
</tr>
<tr>
<td>refractory celiac disease</td>
<td>plus referral to nutritionist or gastroenterologist</td>
</tr>
<tr>
<td>celiac crisis</td>
<td>plus rehydration + correction of electrolyte abnormalities</td>
</tr>
<tr>
<td>celiac crisis</td>
<td>adjunct corticosteroid</td>
</tr>
</tbody>
</table>
## Treatment options

<table>
<thead>
<tr>
<th>Ongoing</th>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>celiac disease</td>
<td>1st</td>
<td>gluten-free diet</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» The gluten-free diet is the only accepted treatment of celiac disease. Adherence is difficult, and dietary changes may lead to deficiencies in fiber and other nutrients, so consultation with a nutritionist should be sought. Although the safety of oats in celiac disease has been controversial, there is substantial evidence that oats that are not contaminated by wheat or barley are safe for the vast majority of patients with celiac disease. In practice, oats should be avoided until the patient is in clinical remission, and then wheat-free oats may be gradually added to the diet.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» A number of agents are under investigation, but these treatments appear unlikely to replace the gluten-free diet. Rather, they may be used to allow for laxity in situations of low-level gluten exposure: for example, in food additives.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>plus</td>
<td>calcium and vitamin D supplementation ± iron</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» After diagnosis, patients should be checked for common deficiencies including iron and vitamin D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» All patients with celiac disease should take calcium and vitamin D supplements. Iron should only be given to individuals with iron deficiency.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» Bone mineral density should be evaluated after approximately 1 year on gluten-free diet to assess for osteopenia or osteoporosis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>» Doses are individualized according to age and presence of deficiencies or decreased bone density.</td>
</tr>
</tbody>
</table>

### Primary options

- **ergocalciferol (vitamin D2):** 1000-2000 units orally once daily
- **calcium carbonate:** 1000-1500 mg/day orally given in 3-4 divided doses

Dose refers to elemental calcium.
<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>celiac crisis</td>
<td>plus</td>
<td>rehydration + correction of electrolyte abnormalities</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Celiac crisis is rare and presents with hypovolemia, severe watery diarrhea, acidosis, hypocalcemia, and hypoalbuminemia. Patients are often emaciated and have nutritional deficiencies caused by longstanding, untreated celiac disease.</td>
</tr>
<tr>
<td>refractory celiac disease</td>
<td>plus</td>
<td>referral to nutritionist or gastroenterologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For individuals who do not respond to a gluten-free diet, the most common problem is continued gluten exposure. The initial step in the evaluation should be repeating immunoglobulin A-tissue transglutaminase (IgA-tTG) titer and referral to a nutritionist with expertise in celiac disease. If there is no evidence of continuing gluten intake, referral to a gastroenterologist with experience in the evaluation of nonresponsive celiac disease is recommended.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The outlook for patients can be poor. They should be cared for at a center experienced in celiac disease.</td>
</tr>
<tr>
<td>celiac crisis</td>
<td>adjunct</td>
<td>corticosteroid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In addition to rehydration and correction of electrolyte abnormalities, patients with celiac crisis may benefit from a short course of glucocorticoid therapy until the gluten-free diet takes effect.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If patients are able to take oral medications, budesonide may be used initially. If this is not effective, prednisone or an equivalent systemic corticosteroid can be started, and should be tapered slowly after the patient is able to</td>
</tr>
<tr>
<td>Patient group</td>
<td>Tx line</td>
<td>Treatment</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>maintain hydration and nutritional status without intravenous supplementation.</td>
</tr>
</tbody>
</table>

**Primary options**

- **budesonide**: 9 mg orally (enteric-coated) once daily

**OR**

**Primary options**

- **prednisone**: 40-60 mg orally once daily initially then taper dose slowly

**OR**

**Secondary options**

- **methylprednisolone sodium succinate**: consult specialist for guidance on dose
Emerging

Endopeptidases
Glutenase ALV003 may digest gluten within the intestinal lumen into nonantigenic peptides. Based on a phase II trial, it appears to attenuate gluten-induced mucosal injury in the small intestine in patients with celiac disease.[63]

Zonulin antagonists
These antagonists may strengthen tight junctions and prevent gluten from infiltrating the mucosa.[64]

tTG inhibitors
Tissue transglutaminase (tTG) inhibitors may prevent the deamidation and resultant potentiation of gliadin peptides.[16]

Blockers of the interaction of gliadin peptides with HLA-DQ2 or -DQ8
These agents may prevent T cell activation.

Immune modulation
Immune modulation may restore gluten tolerance.[65]

Probiotics
Early evidence suggests some strains of probiotics may assist with intestinal healing.[66]
**Recommendations**

**Monitoring**

Although not supported by data, many clinicians will check immunoglobulin A-tissue transglutaminase (IgA-tTG) titers every 3 months until normalized and then yearly as a rough test of diet adherence. In most cases, IgA-tTG titer should normalize within 6 to 9 months.[77]

Refer to a nutritionist at diagnosis and yearly to instruct and monitor gluten-free diet adherence.

Treat deficiency states present at diagnosis with oral supplementation and monitor until resolved.

Repeat endoscopy is not routinely necessary in patients responding well clinically and in whom IgA-tTG has normalized.

**Patient instructions**

Immediately upon diagnosis the patient should be recommended to avoid all products containing wheat, rye, barley, and spelt. [National Digestive Diseases Information Clearinghouse: celiac disease] [Gluten-free drugs] [New England Celiac Organization] Although not technically a trigger for celiac disease, oats should be avoided at the outset as many products are contaminated with wheat and a minority of celiac patients may be oat-intolerant. The gluten-free diet is demanding, especially at the outset, and referral to both a nutritionist skilled in celiac disease and a local support/advocacy group is strongly recommended. Patients should be reassured that adopting the diet is a challenge and mistakes and difficulties adjusting early on are common.

**Complications**

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>osteoporosis/osteopenia</td>
<td>variable</td>
<td>medium</td>
</tr>
</tbody>
</table>

Reduced bone mineral density is common in celiac disease and often improves significantly within 1 year of gluten withdrawal.

Although no evidence supports this, bone mineral density may be checked in patients after they have been on a gluten-free diet for 1 year.[74] [75] [76]

| dermatitis herpetiformis      | variable  | medium     |

Dermatitis herpetiformis is the skin manifestation of active celiac disease. Episodes can recur even on a strict gluten-free diet. In these cases, treatment with dapsone in conjunction with the gluten-free diet may be helpful.

| malignancy                   | variable  | low        |

Some malignancies are more common in patients with celiac disease, including intestinal and extraintestinal lymphoma and carcinomas of the upper digestive tract.

The magnitude of increased risk is moderate (standardized incidence ratio of 1.3, 95% CI 1.2 to 1.5 in one study[71]) and appears to normalize within a few years of gluten withdrawal. No additional screening is recommended.[72] [73]
Complications | Timeframe | Likelihood
--- | --- | ---
idiopathic recurrent acute pancreatitis/chronic pancreatitis | variable | low

Celiac disease may present as recurrent acute pancreatitis or be complicated by chronic pancreatitis. Both conditions are unusual and do not warrant screening. In patients with treated celiac disease and persistent diarrhea, pancreatic exocrine insufficiency can be considered.

Prognosis

The prognosis for patients with celiac disease is good.[69] Most, up to 90% in some studies, will have complete and lasting resolution of symptoms on a gluten-free diet alone. For the 10% with persistent symptoms, most of these will be attributed to ongoing gluten exposure, lactose intolerance, and irritable bowel syndrome. Less than 1% can be expected to develop refractory celiac disease.[70]
## Diagnostic guidelines

### International


**Published by:** US Preventive Services Task Force  
**Last published:** 2017

**Summary:** Concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic adults, adolescents, and children.


**Published by:** American College of Gastroenterology  
**Last published:** 2013

**Summary:** Recommendations for the diagnosis and management of patients with celiac disease.


**Published by:** North American Society for Pediatric Gastroenterology, Hepatology and Nutrition  
**Last published:** 2005

**Summary:** Diagnosis guidelines pertaining specifically to the pediatric population.


**Published by:** World Gastroenterology Organisation  
**Last published:** 2016

**Summary:** Recommends diagnostic tests for celiac disease, including intestinal biopsy and specific serum antibodies (IgA EMA, IgA tTg, IgA AGA, IgG AGA). Details the clinical presentation, epidemiology, and differential diagnosis for celiac disease.
International


Published by: National Institute for Health and Care Excellence (UK)  Last published: 2015
Summary: Covers assessment of celiac disease in children, young people, and adults.


Published by: European Society of Gastrointestinal Endoscopy  Last published: 2015
Summary: Recommends against the use of small-bowel capsule endoscopy for suspected celiac disease but suggests that capsule endoscopy could be used in patients unwilling or unable to undergo conventional endoscopy.


Published by: European Society for Paediatric Gastroenterology, Hepatology, and Nutrition  Last published: 2012
Summary: Guidelines for the diagnosis of celiac disease, based on scientific and technical developments using an evidence-based approach.
Celiac disease

Guidelines

**International**

Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition consensus report on celiac disease

*Published by:* Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition  
*Last published:* 2008

*Summary:* Reviews current knowledge, controversies, and emerging research in celiac disease including issues related to diagnosis.

---

**Treatment guidelines**

**International**


*Published by:* Academy of Nutrition and Dietetics (American Dietetic Association)  
*Last published:* 2009

*Summary:* Covers medical nutrition therapy for people with celiac disease, with the primary goals to promote optimal health, prevent and treat malabsorption/malnutrition and other comorbidities, and improve quality of life.

Guideline for the diagnosis and treatment of celiac disease in children

*Published by:* North American Society for Pediatric Gastroenterology, Hepatology and Nutrition  
*Last published:* 2005

*Summary:* Treatment guidelines pertaining specifically to the pediatric population.
International


Published by: Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition
Last published: 2008
Summary: Reviews current knowledge, controversies, and emerging research in celiac disease including issues related to treatment.


Published by: Association of European Coeliac Societies
Last published: 2016
Summary: Outlines recommendations for the management of celiac disease in adolescents and young adults, and how to facilitate the transition to adult healthcare for patients with celiac disease.
## Online resources

1. [National Digestive Diseases Information Clearinghouse: celiac disease](#)  
2. [Gluten-free drugs](#)  
3. [New England Celiac Organization](#)
Celiac disease

Key articles


References


32. Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment Pharmacol Ther. 2006;24:47-54. Full text Abstract


44. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(suppl 1):S78-S90.  Abstract


Images

Figure 1: Histologic image of small intestinal villous atrophy and crypt hyperplasia
From the personal collection of D.A. Leffler; used with permission

Figure 2: Histologic image of small intestinal villi showing resolution of intestinal injury on gluten-free diet
From the personal collection of D.A. Leffler; used with permission
Figure 3: Photograph of small intestinal villi affected by celiac disease
From the personal collection of D.A. Leffler; used with permission

Figure 4: Photograph of normal small intestinal villi
From the personal collection of D.A. Leffler; used with permission
Figure 5: Scalloping of the duodenal mucosa in a patient with celiac disease

From the personal collection of D.A. Leffler; used with permission
Figure 6: Scalloping of the duodenal mucosa in a patient with celiac disease

From the personal collection of D.A. Leffler; used with permission
Disclaimer

This content is meant for medical professionals. The BMJ Publishing Group Ltd ("BMJ Group") tries to ensure that the information provided is accurate and up-to-date, but we do not warrant that it is. The BMJ Group does not advocate or endorse the use of any drug or therapy contained within nor does it diagnose patients. Medical professionals should use their own professional judgement in using this information and caring for their patients and the information herein should not be considered a substitute for that.

This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. We strongly recommend that users independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your patient. This information is provided on an “as is” basis and to the fullest extent permitted by law the BMJ Group assumes no responsibility for any aspect of healthcare administered with the aid of this information or any other use of this information.

View our full Website Terms and Conditions.
Contributors:

// Authors:

Ciaran P. Kelly, MD  
Professor of Medicine  
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA  
DISCLOSURES: CPK declares that he has no competing interests.

Daniel A. Leffler, MD, MS  
Associate Professor of Medicine  
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA  
DISCLOSURES: DAL declares that he has no competing interests.

// Peer Reviewers:

Richard Farrell, MD, MRCPI  
Consultant Gastroenterologist  
Connolly Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland  
DISCLOSURES: RF declares that he has no competing interests.

Alessio Fasano, MD  
Professor of Pediatrics, Medicine, and Physiology  
Director of Mucosal Biology Research Center, University of Maryland School of Medicine, Baltimore, MD  
DISCLOSURES: AF has financial interests in Alba Therapeutics, a company that is developing treatments for celiac disease as alternatives to the gluten-free diet.